jueves, 30 de julio de 2020

Risk of Loss of Coordination When Deep Brain Stimulators Are Used to Treat Parkinson’s Disease

https://www.fda.gov/medical-devices/safety-communications/risk-loss-coordination-during-water-related-activities-parkinsons-patients-deep-brain-stimulators?utm_campaign=2020-07-30%20Safety%20Comm%20Parkinsons%20Deep%20Brain%20Stimulators&utm_medium=email&utm_source=Eloqua

Risk of loss of coordination during water-related activities in Parkinson’s Patients with Deep Brain Stimulators: FDA Safety Communication

The U.S. Food and Drug Administration (FDA) would like to remind patients and health care providers about a potential safety risk associated with the use of deep brain stimulation (DBS) devices for the treatment of Parkinson’s Disease. Specifically, patients with DBS devices may experience a loss of coordination during water-related activities such as swimming.

The safety communication provides important information about DBS, including:
  • The potential risk of losing coordination during water-related activities requiring coordinated movements while using DSB
  • Recommendations for patients, caregivers, and health care providers
  • Instructions for reporting problems experienced with a DBS device

Questions?

If you have questions about this safety communication, contact the Division of Industry and Consumer Education (DICE).

No hay comentarios:

Publicar un comentario